>

List of Biologics Coming Off Patents Between 2022 to 2027

Biologics have been observed to be a rapidly evolving area within biotechnology. 

Cancer, autoimmune diseases, and diabetes treatments account for over 60% of the biologics market. Thus making it extremely expensive with prices increasing by the day.

According to the World Health Organization (WHO), these high prices are restricting the healthcare systems from providing affordable, population-wide access to such medicines. This creates a huge space for generic companies to manufacture biosimilars of the originator biologics whose patents have expired.

As a result, generic companies (hey there!) are continuously searching for biologics with a soon-to-be-expired label. To make it easier for them (you), we’ve collated not just the biologics names, but also included other information like yearly sales, treatment, dosage, and the brand as well as company names which could help them (you) easily choose a biologic most profitable to develop a biosimilar. 

So, without any delay, let’s get to the list of biologics patents expiring between 2022-2027.

Biologics Patents Expiration

PERJETA
Pertuzumab

Sales:
$4.73 Billion (2021)

More information about this Drug

Patents Expiration Date
US7618631B2 April 16, 2022
US8337856B2 September 30, 2023
US7862817B2 June 1, 2025
US7097840B2 July 25, 2026

Dosage:
Company: Genentech
Treatment: HER2-positive Breast Cancer

VYROLOGIX
Leronlimab

Sales:
$576 Million (2020)

More information about this Drug

Patents Expiration Date
US7666419B2 February 21, 2023
US7851600B2 February 21, 2023
US7122185B2 June 1, 2024

Dosage:
Company: Cytodyn Inc.
Treatment: HIV Infection

STELARA
Ustekinumab

Sales:
$9.13 Billion (2021)

More information about this Drug

Patents Expiration Date
US7279157B2 January 13, 2022
US9409984B2 February 27, 2022
US7166285B2 May 3, 2022
US8080247B2 August 2, 2022
US6902734B2 September 25, 2023

Dosage: Injection
Company: Janssen Pharmaceuticals
Treatment: Plaque Psoriasis and Psoriatic Arthritis

BENLYSTA
Belimumab

Sales:
$747 Million (2019)

More information about this Drug

Patents Expiration Date
US7605236B2 August 5, 2022
US7220840B2 July 11, 2023
US7879328B2 July 17, 2023
US7138501B2 March 9, 2025

Dosage: Injection
Company: GlaxoSmithKline
Treatment: Systemic Lupus Erythematosus

CYRAMZA
Ramucirumab

Sales:
$1.033 Billion (2020)

More information about this Drug

Patents Expiration Date
US8057791B2 December 07, 2023
US7498414B2 January 31, 2026

Dosage:
Company: ImClone Systems Inc.
Treatment: Solid Tumors

ELELYSO
Taliglucerase Alfa

Sales:

More information about this Drug

Patents Expiration Date
US8227230B2 February 24, 2024
US8741620B2 February 24, 2024
US9220737B2 February 24, 2024
US7951557B2 July 01, 2025
US8790641B2 October 18, 2025

Dosage:
Company: Protalix and Pfizer
Treatment: Type 1 Gaucher disease

IXIARO
Japanese Encephalitis Vaccine

Sales:
$106.75 Million (2020)

More information about this Drug

Patents Expiration Date
US6309650 December 30, 2022

Dosage: Injection
Company: BIKEN and Sanofi Pasteur
Treatment: Japanese encephalitis

JETREA
Ocriplasmin

Sales:
$7.8 Million (2016)

More information about this Drug

Patents Expiration Date
US7445775 October 17, 2026

Dosage: Intravitreal Injection
Company: ThromboGenics
Treatment: Symptomatic Vitreomacular Adhesion

KADCYLA
Trastuzumab Emtansine

Sales:
$960 Million (2018)

More information about this Drug

Patents Expiration Date
US7618631B2 April 16, 2022
US8337856B2 September 30, 2023
US7862817B2 June 1, 2025
US7097840B2 July 25, 2026

Dosage: Intravenous Infusion
Company: Genentech
Treatment: HER2-positive Breast Cancer

KALBITOR
Ecallantide

Sales:
$67.3 Million (2017)

More information about this Drug

Patents Expiration Date
US7276480 June 6, 2023

Dosage: Injection
Company: Takeda Pharmaceutical
Treatment: Hereditary Angioedema

MYALEPT
Metreleptin

Sales:
$71.4 Million (2018)

More information about this Drug

Patents Expiration Date
US8318666B2 October 22, 2022
US7183254B2 July 17, 2027

Dosage: Injection
Company: Amryt Pharmaceutical
Treatment: Dyslipidemia

NPLATE
Romiplostim

Sales:
$227 Million (2020)

More information about this Drug

Patents Expiration Date
US6835809 January 19, 2022

Dosage: Injection
Company: Amgen
Treatment: Low blood platelet counts

TANZEUM
Albiglutide

Sales:
$160 Million (2016)

More information about this Drug

Patents Expiration Date
US7238660B2 December 23, 2022
US7238667B2 December 23, 2022
US8071539B2 December 23, 2022
US9221896B2 December 23, 2022
US9296809B2 December 23, 2022
US7977306B2 January 2, 2023
US7799759B2 February 11, 2023
US8993517B2 February 12, 2023
US7189690B2 October 2, 2023
US7592010B2 December 1, 2023
US7521424B2 January 20, 2024
US8287859B2 February 11, 2024
US8012464B2 May 21, 2024
US8143026B2 February 9, 2025
US8211439B2 April 11, 2025
US7847079B2 October 4, 2025
US7141547B2 April 22, 2027

Dosage: Injection
Company: GlaxoSmithKline
Treatment: Type 2 Diabetes

VICTOZA
Liraglutide

Sales:
$2.7 Billion (2018)

More information about this Drug

Patents Expiration Date
US6268343 August 22, 2022

Dosage: Injection
Company: Novo Nordisk
Treatment: Type 2 Diabetes

YERVOY
Ipilimumab

Sales:
$1.7 Billion (2020)

More information about this Drug

Patents Expiration Date
US6984720 February 8, 2022

Dosage: Intravenous Infusion
Company: Bristol‑Myers Squibb
Treatment: Melanoma

DARZALEX
Daratumumab

Sales:
$4.1 Billion (2020)

More information about this Drug

Patents Expiration Date
US7829673B2 August 27, 2026
US9187565B2 December 5, 2027

Dosage: Intravenous Infusion
Company: Genmab
Treatment: Myeloma

BLINCYTO
Blinatumomab

Sales:
$103 Million (2020)

More information about this Drug

Patents Expiration Date
US7635472B2 November 28, 2025

Dosage: Intravenous Infusion
Company: Micromet (acquired by Amgen)
Treatment: Acute Lymphoblastic Leukemia

CIMZIA
Certolizumab Pegol

Sales:
$2.04 Billion (2020)

More information about this Drug

Patents Expiration Date
US7186820B2 February 3, 2022
US7977464B2 February 13, 2022
US7012135B2 February 13, 2024

Dosage: Subcutaneous Injection
Company: UCB
Treatment: Crohn’s Disease, Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

ILARIS
Canakinumab

Sales:
$576 Million (2020)

More information about this Drug

Patents Expiration Date
US7446175B2 December 22, 2022

Dosage: Intravenous Infusion
Company: Novartis
Treatment: Systemic Juvenile Idiopathic Arthritis

SIMPONI
Golimumab

Sales:
$576 Million (2020)

More information about this Drug

Patents Expiration Date
US7521206B2 March 20, 2022
US8241899B2 November 3, 2022
US7250165B2 February 3, 2024
US7691378B2 September 19, 2024

Dosage: Subcutaneous Injection
Company: Janssen Biotech
Treatment: Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

TRULICITY
Dulaglutide

Sales:
$5.07 Billion (2020)

More information about this Drug

Patents Expiration Date
US10369003B2 October 15, 2024
US10376376B2 October 15, 2024
US10610371B2 October 15, 2024
US11083591B2 October 15, 2024
US9056018B2 October 15, 2024
US9867712B2 October 15, 2024
US10695187B2 June 28, 2025
US8273854B2 May 15, 2026
US10130493B2 July 17, 2026
US8535379B2 December 13, 2026
US11135072B2 April 11, 2027
US7452966B2 December 7, 2027

Dosage: Subcutaneous Injection
Company: Eli Lilly and Company
Treatment: Type 2 Diabetes

ZALTRAP
Aflibercept

Sales:
$15.88 Million (2020)

More information about this Drug

Patents Expiration Date
US7399612B2 November 6, 2023
US7279159B2 November 11, 2024

Dosage: Intravitreal Injection
Company: Regeneron Pharmaceuticals
Treatment: Wet Macular Degeneration and Metastatic Colorectal Cancer

SYLVANT
Siltuximab

Sales:

More information about this Drug

Patents Expiration Date
US7612182B2 October 26, 2022
US7955597B2 October 26, 2022
US7833786B2 June 7, 2023
US7291721B2 September 13, 2027

Dosage: Intravenous Infusion
Company: Eusa Pharma
Treatment: Metastatic Renal Cell Cancer, Prostate Cancer, and Castleman’s Disease

LARTRUVO
Olaratumab

Sales:
$304.7 Million (2018)

More information about this Drug

Patents Expiration Date
US8574578B2 June 19, 2026
US8128929B2 December 20, 2027

Dosage: Intravenous Infusion
Company: Eli Lilly and Company
Treatment: Solid Tumors

OPDIVO
Nivolumab

Sales:
$7.92 Billion (2020)

More information about this Drug

Patents Expiration Date
US9393301B2 July 2, 2023
US8168179B2 July 2, 2023
US9067999B1 July 2, 2023
US9073994B2 July 2, 2023
US9439962B2 July 2, 2023
US9402899B2 February 5, 2024
US7595048B2 August 8, 2024
US8728474B2 August 8, 2024

Dosage: Intravenous Infusion
Company: Bristol‑Myers Squibb
Treatment: Different Types of Cancer

PORTRAZZA
Necitumumab

Sales:

More information about this Drug

Patents Expiration Date
US7598350B2 March 21, 2025

Dosage: Intravenous Infusion
Company: Eli Lilly and Company
Treatment: Metastatic Squamous Non-small Cell Lung Cancer

PROLIA
Denosumab

Sales:
$4.6 Billion (2020)

More information about this Drug

Patents Expiration Date
US8409578B2 June 25, 2022
US8058418B2 November 30, 2023
US7364736B2 February 19, 2025

Dosage: Subcutaneous Injection
Company: Amgen
Treatment: Osteoporosis

TALTZ
Ixekizumab

Sales:
$1.78 Billion (2020)

More information about this Drug

Patents Expiration Date
US8110191B2 December 5, 2026
US7838638B2 February 4, 2030

Dosage: Subcutaneous Injection
Company: Eli Lilly and Company
Treatment: Autoimmune Diseases

ARANESP
Darbepoetin Alfa

Sales:
$629 Million (2020)

More information about this Drug

Patents Expiration Date
US7217689B1 May 15, 2024

Dosage: Intravenous Infusion
Company: Amgen
Treatment: Anemia

EYLEA
Aflibercept

Sales:
$8.36 Billion (2020)

More information about this Drug

Patents Expiration Date
US7279159B2 November 11, 2024

Dosage: Intravitreal Injection
Company: Regeneron Pharmaceuticals
Treatment: Wet Macular Degeneration and Metastatic Colorectal Cancer

ARZERRA
Ofatumumab

Sales:

More information about this Drug

Patents Expiration Date
US8529902B2 August 2, 2030

Dosage: Intravenous Infusion
Company: Genmab
Treatment: Multiple Sclerosis

Conclusion

Earlier we released a list of 107 drug patents expiring between 2021 to 2025. And while small molecule drugs still dominate the global pharmaceutical market in terms of numbers, many of the most promising new therapies for previously intractable diseases are a result of biologics. Biologics are thus becoming increasingly important to the pharmaceutical market. But having this list is one thing and using it, another.

Developing biosimilars is not going to be as smooth sailing. Generic companies will likely have to face many threats and stiff legal battles depending on the biologic they choose.

With proper threat analysis, companies can save themselves from this torment. Wanna know all about it? Just fill out the form below and we’ll get back to you in no time.

List curated by: Divya Goyal, Life Science Team Authored By: Nidhi, Marketing.

Leave a Comment